Read more
3:41 PM · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

-
-
Open account Download free app

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

23 January 2026, 9:23 AM

Intel: Solid Results, But the Market Says "Not Enough"

22 January 2026, 3:59 PM

Meta Platforms shares surge amid Jefferies 'Buy' recommendation 📈

22 January 2026, 3:36 PM

US Open: Rebound attempt on Wall Street 📈Meta Platforms surges 3.5%

22 January 2026, 2:24 PM

Stock of the Week: TSMC, the heart of the global AI revolution (January 22, 2026)

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits